Aspirin or clopidogrel against valve clots after replacement for aortic stenosis
Compares aspirin and clopidogrel after valve replacement for aortic stenosis.
Key facts
- Who runs it
- Yonsei University
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Aspirin vs Clopidogrel After TAVR
- Status
- Recruiting
- People taking part
- 270 people, planned
- Started
- 2 Feb 2023
- Expected to end
- 21 Jul 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Aspirin single antiplatelet therapy
- Clopidogrel single antiplatelet therapy
- Record updated
- 30 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had TAVR (a valve replaced through a tube in a blood vessel) for severe aortic stenosis with symptoms. It compares aspirin with clopidogrel after the procedure.
- Age
- Older than 19 years (minimum age 19 Years).
- Sex
- All sexes can join.
- Disease stage
- Severe aortic stenosis (narrowing of the heart's aortic valve) with symptoms, treated with TAVR.
- Earlier treatment
- Must have had TAVR. People who had a valve-in-valve TAVR cannot join.
Main reasons for not taking part
- Needing two blood-thinning platelet drugs for longer than 4 weeks, or needing blood thinners (anticoagulants).
- Stroke or TIA (mini-stroke) within 6 months.
- Severe kidney disease, stage 4 or 5 (eGFR <30mL/min).
- Cardiogenic shock or unstable blood pressure and circulation.
- Allergy to aspirin or clopidogrel, or a reason they cannot be used; planned major surgery.
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Patients >19 years old
- Patients who underwent TAVR symptomatic severe AS
- Provision of informed consent
Who cannot take part
- Patients requiring dual antiplatelet therapy longer than 4 weeks
- Planned major surgery
- Indication for anticoagulation therapy
- Any conditions requiring specific antiplatelet therapy aspirin or clopidogrel
- History of stroke or transient ischemic attack (TIA) within 6 months
- Hypersensitivity or contraindication to aspirin or clopidogrel
- Chronic kidney disease stage 4 or 5 (eGFR <30mL/min)
- Cardiogenic shock or hemodynamic instability
- Valve-in-valve TAVR procedure
Where in South Korea
- Yonsei University Health System, Severance HospitalSeoul, South KoreaContact: Young-Guk Ko, MD, PhDTaking people
About the trial
What the trial wants to find out
Currently, the optimal antithrombotic therapy after transcatheter aortic valve replacement (TAVR) remains still unknown., The purpose of the study is to compare aspirin versus clopidogrel monoantiplatelet therapy for preventive effect on leaflet thrombosis in patients undergoing TAVR for severe aortic stenosis. This study is designed as a prospective, multicenter, open label, randomized controlled study. Eligible patients will be randomized to aspirin or clopidogrel monotherapy after TAVR. Patients will have dual antiplatelet therapy of aspirin 100 mg and clopidogrel 75 mg for 4 weeks after TAVR and then subsequent monoantiplatelet therapy of either aspirin 100 mg or clopidogrel 75 mg according to the randomization. Leaflet thrombosis will be assessed with cardiac computed tomography (CT) and transthoracic echocardiography at 3 months after TAVR. Patients will be clinically followed for 6 months. The primary endpoint is the Incidence of leaflet thrombosis on cardiac CT at 3 months.
The 2 groups in the trial
- Aspirin groupExisting treatment, for comparison
Patients receive the aspirin (100 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
Treatment: Aspirin single antiplatelet therapy
- Clopidogrel groupTreatment being tested
Patients receive the clopidogrel (75 mg/day) single antiplatelet therapy after 4 weeks of dual antiplatelet therapy of aspirin (100 mg/day) and clopidogrel (75 mg/day) after TAVR.
Treatment: Clopidogrel single antiplatelet therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Aspirin Versus Clopidogrel for Leaflet Thrombosis Prevention in Patients Undergoing Transcatheter Aortic Valve Replacement: ACLO-TAVR Trial
- Plain-language title
- Aspirin or clopidogrel against valve clots after replacement for aortic stenosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 30 June 2026